Skin nerve &agr;-synuclein deposits: A biomarker for idiopathic Parkinson disease

Objective:To investigate (1) whether phosphorylated &agr;-synuclein deposits in skin nerve fibers might represent a useful biomarker for idiopathic Parkinson disease (IPD), and (2) the underlying pathogenesis of peripheral neuropathy associated with IPD. Methods:Twenty-one well-characterized patients with IPD were studied together with 20 patients with parkinsonisms assumed not to have &agr;-synuclein deposits (PAR; 10 patients fulfilling clinical criteria for vascular parkinsonism, 6 for tauopathies, and 4 with parkin mutations) and 30 controls. Subjects underwent nerve conduction velocities from the leg to evaluate large nerve fibers and skin biopsy from proximal (i.e., cervical) and distal (i.e., thigh and distal leg) sites to study small nerve fibers and deposits of phosphorylated &agr;-synuclein considered the pathologic form of &agr;-synuclein. Results:Patients with IPD showed a small nerve fiber neuropathy prevalent in the leg with preserved large nerve fibers. PAR patients showed normal large and small nerve fibers. Phosphorylated &agr;-synuclein was not found in any skin sample in PAR patients and controls, but it was found in all patients with IPD in the cervical skin site. Abnormal deposits were correlated with leg epidermal denervation. Conclusions:The search for phosphorylated &agr;-synuclein in proximal peripheral nerves is a sensitive biomarker for IPD diagnosis, helping to differentiate IPD from other parkinsonisms. Neuritic inclusions of &agr;-synuclein were correlated with a small-fiber neuropathy, suggesting their direct role in peripheral nerve fiber damage. Classification of evidence:This study provides Class III evidence that the presence of phosphorylated &agr;-synuclein in skin nerve fibers on skin biopsy accurately distinguishes IPD from other forms of parkinsonism.

[1]  R. Djaldetti,et al.  Skin biopsy for assessment of autonomic denervation in Parkinson’s disease , 2006, Journal of Neural Transmission.

[2]  M. Feany,et al.  New genetic insights into Parkinson's disease. , 2004, The New England journal of medicine.

[3]  E. Masliah,et al.  α-Synuclein is phosphorylated in synucleinopathy lesions , 2002, Nature Cell Biology.

[4]  J. Hughes,et al.  Accuracy of clinical diagnosis of idiopathic Parkinson's disease: a clinico-pathological study of 100 cases. , 1992, Journal of neurology, neurosurgery, and psychiatry.

[5]  S. Braune The role of cardiac metaiodobenzylguanidine uptake in the differential diagnosis of parkinsonian syndromes , 2001, Clinical Autonomic Research.

[6]  D. Calne Progress in Parkinson's disease. , 1984, The New England journal of medicine.

[7]  T. Iwatsubo,et al.  Lewy Body Pathology Involves Cutaneous Nerves , 2008, Journal of neuropathology and experimental neurology.

[8]  O. Levy,et al.  The neuropathology of genetic Parkinson's disease , 2012, Movement disorders : official journal of the Movement Disorder Society.

[9]  L. Santoro,et al.  Neuropathy in idiopathic Parkinson disease: An Iatrogenic problem? , 2011, Annals of neurology.

[10]  P. Cortelli,et al.  Peripheral Autonomic Neuropathy: Diagnostic Contribution of Skin Biopsy , 2012, Journal of neuropathology and experimental neurology.

[11]  A. Probst,et al.  α‐Synuclein pathology of the spinal and peripheral autonomic nervous system in neurologically unimpaired elderly subjects , 2006, Neuropathology and applied neurobiology.

[12]  P. Barone,et al.  Neuropathy and levodopa in Parkinson's disease: Evidence from a multicenter study , 2013, Movement disorders : official journal of the Movement Disorder Society.

[13]  Bernardo Lanzillo,et al.  Sensory deficit in Parkinson's disease: evidence of a cutaneous denervation. , 2008, Brain : a journal of neurology.

[14]  S. Wiebe,et al.  Levodopa, methylmalonic acid, and neuropathy in idiopathic Parkinson disease , 2010, Annals of neurology.

[15]  Clinical and neuropathological criteria for frontotemporal dementia. The Lund and Manchester Groups. , 1994, Journal of neurology, neurosurgery, and psychiatry.

[16]  H. Benamer,et al.  Differentiating vascular parkinsonism from idiopathic Parkinson's disease: A systematic review , 2010, Movement disorders : official journal of the Movement Disorder Society.

[17]  L. Hakamies,et al.  [Corticobasal degeneration]. , 2001, Duodecim; laaketieteellinen aikakauskirja.

[18]  T. Kanda,et al.  Changes of unmyelinated nerve fibers in sural nerve in amyotrophic lateral sclerosis, Parkinson’s disease and multiple system atrophy , 2009, Acta Neuropathologica.

[19]  Maria Nolano,et al.  Skin sympathetic adrenergic innervation: An immunofluorescence confocal study , 2006, Annals of neurology.

[20]  Tapan P. Patel,et al.  Exogenous α-Synuclein Fibrils Induce Lewy Body Pathology Leading to Synaptic Dysfunction and Neuron Death , 2011, Neuron.

[21]  A. Schapira Recent developments in biomarkers in Parkinson disease , 2013, Current opinion in neurology.

[22]  A. Probst,et al.  New insights into the pathology of Parkinson’s disease: does the peripheral autonomic system become central? , 2008, European journal of neurology.

[23]  P. Cortelli,et al.  Skin sympathetic fiber &agr;-synuclein deposits: A potential biomarker for pure autonomic failure , 2013, Neurology.

[24]  Yasuo Miki,et al.  Clinical availability of skin biopsy in the diagnosis of Parkinson's disease , 2010, Neuroscience Letters.

[25]  C. Tanner,et al.  Projected number of people with Parkinson disease in the most populous nations, 2005 through 2030 , 2007, Neurology.

[26]  S. Gilman,et al.  Diagnostic criteria for Parkinson disease. , 1999, Archives of neurology.

[27]  R. Freeman,et al.  Quantification of sudomotor innervation: A comparison of three methods , 2010, Muscle & nerve.

[28]  Shalini Jha,et al.  The diagnosis of Parkinson's disease. , 2003, Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology.

[29]  E. Masliah,et al.  alpha-Synuclein is phosphorylated in synucleinopathy lesions. , 2002, Nature cell biology.

[30]  M. Hallett,et al.  Clinical research criteria for the diagnosis of progressive supranuclear palsy (Steele-Richardson-Olszewski syndrome) , 1996, Neurology.

[31]  H. Shill,et al.  Multi-organ distribution of phosphorylated α-synuclein histopathology in subjects with Lewy body disorders , 2010, Acta Neuropathologica.

[32]  Claire Henchcliffe,et al.  Biomarkers in Parkinson's disease: an update. , 2012, Current opinion in neurology.

[33]  D. Goldstein,et al.  Sympathetic cardioneuropathy in dysautonomias. , 1997, Advances in pharmacology.

[34]  L. Wilkins Skin sympathetic fiber α-synuclein deposits: A potential biomarker for pure autonomic failure , 2014, Neurology.